Description
This entry-level metabolic stack combines Semaglutide for systemic appetite suppression and caloric reduction, AOD-9604 for direct lipolysis (fat breakdown) without affecting insulin or muscle mass, and MOTS-c for mitochondrial optimization and improved insulin sensitivity. This multi-pathway approach targets fat loss from three distinct angles: reducing intake via GLP-1 activation, mobilizing stored triglycerides via AOD-9604, and enhancing the cellular machinery’s ability to oxidize fatty acids via MOTS-c.
Research Peptides:
- Semaglutide 10mg
- AOD-9604 5mg
- MOTS-c 10mg


Reviews
There are no reviews yet.